Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.

Abstract

Testotoxicosis, a form of gonadotropin-independent precocious puberty, results from an activating mutation of the luteinizing hormone receptor expressed in testicular Leydig cells. Affected males experience early testosterone secretion, virilization, advancing bone age, and resultant short stature. Recently, the use of combination therapy with a potent antiandrogen agent (bicalutamide) and a third-generation aromatase inhibitor (anastrozole or letrozole) was reported to yield encouraging short-term results. We present here the results of longer-term treatment (4.5 and 5 years) with this combination therapy in 2 boys who demonstrated that it is well tolerated, slows bone-age advancement in the face of continued linear growth, and prevents progression of virilization.

• Authors: Anne M Lenz, Dorothy Shulman, Erica A Eugster, Samar Rahhal, John S Fuqua, Ora H Pescovitz, Katherine A Lewis
• Journal: Pediatrics (Pediatrics) Vol. 126 Issue 3 Pg. e728-33 (Sep 2010) ISSN: 1098-4275 [Electronic] United States
• PMID: 20713483 (Publication Type: Case Reports, Journal Article)

Chemical References

• Androgen Antagonists
• Anilides
• Aromatase Inhibitors
• Nitriles
• Tosyl Compounds
• Triazoles
• Anastrozole
• Testosterone
• Letrozole
• bicalutamide

Topics

• Anastrozole
• Androgen Antagonists (therapeutic use)
• Anilides (therapeutic use)
• Aromatase Inhibitors (therapeutic use)
• Child, Preschool
• Humans
• Letrozole
• Male
• Nitriles (therapeutic use)
• Puberty, Precocious (blood, etiology)
• Testosterone (blood)
• Tosyl Compounds (therapeutic use)
• Triazoles (therapeutic use)